Cargando…
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028563/ https://www.ncbi.nlm.nih.gov/pubmed/35457120 http://dx.doi.org/10.3390/ijms23084305 |
_version_ | 1784691650756345856 |
---|---|
author | Lange, Naomi F. Graf, Vanessa Caussy, Cyrielle Dufour, Jean-François |
author_facet | Lange, Naomi F. Graf, Vanessa Caussy, Cyrielle Dufour, Jean-François |
author_sort | Lange, Naomi F. |
collection | PubMed |
description | Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause a significant burden worldwide and therapeutic strategies are needed. This review provides an overview of the evidence on PPAR-targeted treatment of NAFLD and NASH in individuals with type 2 diabetes mellitus. We considered current evidence from clinical trials and observational studies as well as the impact of treatment on comorbid metabolic conditions such as obesity, dyslipidemia, and cardiovascular disease. Future areas of research, such as possible sexually dimorphic effects of PPAR-targeted therapies, are briefly reviewed. |
format | Online Article Text |
id | pubmed-9028563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90285632022-04-23 PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients Lange, Naomi F. Graf, Vanessa Caussy, Cyrielle Dufour, Jean-François Int J Mol Sci Review Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cause a significant burden worldwide and therapeutic strategies are needed. This review provides an overview of the evidence on PPAR-targeted treatment of NAFLD and NASH in individuals with type 2 diabetes mellitus. We considered current evidence from clinical trials and observational studies as well as the impact of treatment on comorbid metabolic conditions such as obesity, dyslipidemia, and cardiovascular disease. Future areas of research, such as possible sexually dimorphic effects of PPAR-targeted therapies, are briefly reviewed. MDPI 2022-04-13 /pmc/articles/PMC9028563/ /pubmed/35457120 http://dx.doi.org/10.3390/ijms23084305 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lange, Naomi F. Graf, Vanessa Caussy, Cyrielle Dufour, Jean-François PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients |
title | PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients |
title_full | PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients |
title_fullStr | PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients |
title_full_unstemmed | PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients |
title_short | PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients |
title_sort | ppar-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028563/ https://www.ncbi.nlm.nih.gov/pubmed/35457120 http://dx.doi.org/10.3390/ijms23084305 |
work_keys_str_mv | AT langenaomif ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients AT grafvanessa ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients AT caussycyrielle ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients AT dufourjeanfrancois ppartargetedtherapiesinthetreatmentofnonalcoholicfattyliverdiseaseindiabeticpatients |